A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
Latest Information Update: 29 May 2025
At a glance
- Drugs Abiraterone acetate/niraparib (Primary) ; Abiraterone acetate; Niraparib; Prednisone
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms MAGNITUDE
- Sponsors Janssen Research & Development; Janssen-Cilag
Most Recent Events
- 02 May 2025 Planned End Date changed from 19 Feb 2027 to 27 Feb 2027.
- 02 Apr 2025 Planned End Date changed from 19 Mar 2027 to 19 Feb 2027.
- 20 Feb 2025 Planned End Date changed from 19 Feb 2027 to 19 Mar 2027.